A randomized, double-blind, comparative, multi-center study of the safety and efficacy of TG 873870 [Nemonoxacin; Taigen Biotechnology] versus levofloxacin in adult patients with community-acquired pneumonia CAP

Trial Profile

A randomized, double-blind, comparative, multi-center study of the safety and efficacy of TG 873870 [Nemonoxacin; Taigen Biotechnology] versus levofloxacin in adult patients with community-acquired pneumonia CAP

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Nemonoxacin (Primary) ; Levofloxacin
  • Indications Chlamydial infections; Community-acquired pneumonia; Haemophilus infections; Mycoplasma infections; Pneumococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 28 Oct 2008 Results were published at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America - A Joint Meeting.
    • 20 Oct 2008 Primary endpoint 'Clinical cure rate' has been met, according to a TaiGen media release.
    • 20 Oct 2008 Top-line results will be presented at ICAAC/IDSA, according to a TaiGen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top